20 terminated. 20 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Terminated 20 |
| Phase 2 | 3 | Terminated 3 |
Follow Leukemia, B-Cell: new trials by email Literature Review of Leukemia, B-Cell trials Research Report on Leukemia, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) Ublituximab, Umbralisib, Venetoclax - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 / Phase 3 | Terminated | TG Therapeutics, Inc. | 277 | 2019-05-16 | 2024-04-19 |
| Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma Ublituximab, Umbralisib, Bendamustine - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 2 / Phase 3 | Terminated | TG Therapeutics, Inc. | 710 | 2016-05-25 | 2022-07-21 |
| Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia Obinutuzumab, Ublituximab, TGR-1202 - Chronic Lymphocytic Leukemia | Phase 3 | Terminated | TG Therapeutics, Inc. | 603 | 2015-11-19 | 2024-12-13 |
| Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia Idelalisib, Chlorambucil, Obinutuzumab - Chronic Lymphocytic Leukemia | Phase 3 | Terminated | Gilead Sciences | 57 | 2015-04-21 | 2018-11-19 |
| Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Idelalisib, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia | Phase 3 | Terminated | Gilead Sciences | 311 | 2014-02-05 | 2018-11-19 |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Placebo, Rituximab, Idelalisib - Indolent Non-Hodgkin's Lymphomas | Phase 3 | Terminated | Gilead Sciences | 295 | 2013-01-16 | 2018-11-16 |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Idelalisib, Rituximab, Bendamustine - Indolent Non-Hodgkin's Lymphomas | Phase 3 | Terminated | Gilead Sciences | 475 | 2013-01-02 | 2018-11-16 |
| Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia Idelalisib, Ofatumumab - Chronic Lymphocytic Leukemia | Phase 3 | Terminated | Gilead Sciences | 261 | 2012-12-04 | 2019-08-14 |
| Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512) Idelalisib - Chronic Lymphocytic Leukemia | Phase 3 | Terminated | Gilead Sciences | 161 | 2012-10-03 | 2019-08-20 |
| The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases Cholecalciferol, oleum neutralicum - Chronic Lymphoid Leukemia | Phase 3 | Terminated | Semmelweis University | 31 | 2012-01-01 | 2020-07-16 |
| Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy Ofatumumab, Observation - Leukaemia, Lymphocytic, Chronic | Phase 3 | Terminated | Novartis Pharmaceuticals | 480 | 2010-05-06 | 2019-07-30 |
| Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia chlorambucil, tablets, ofatumumab (GSK1841157) infusion - Leukaemia, Lymphocytic, Chronic | Phase 3 | Terminated | Novartis Pharmaceuticals | 447 | 2008-12-22 | 2019-06-25 |
| Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies Fludarabine, Total Body Irradiation, Infusion of Stem Cells - Multiple Myeloma, CLL / SLL | Phase 2 / Phase 3 | Terminated | University of Alabama at Birmingham | 5 | 2008-07-01 | 2017-07-24 |
| Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia rituximab, fludarabine phosphate - Leukemia | Phase 3 | Terminated | Alliance for Clinical Trials in Oncology | 84 | 2008-01-01 | 2020-04-22 |
| Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant moxifloxacin hydrochloride, Placebo - Breast Cancer, Chronic Myeloproliferative Disorders | Phase 3 | Terminated | OHSU Knight Cancer Institute | 240 | 2006-05-01 | 2017-05-09 |
| Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) mycophenolate mofetil, placebo - Cancer | Phase 3 | Terminated | Martin, Paul | 151 | 2004-05-01 | 2013-05-03 |
| Involved-Field Radiation Therapy in Treating Patients With Previously Untreated Stage I or Stage II Low-Grade Non-Hodgkin's Lymphoma radiation therapy - Lymphoma | Phase 3 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 204 | 2001-01-01 | 2012-07-16 |
| Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia Filgrastim, Fludarabine, Cyclophosphamide - Chronic Lymphocytic Leukemia | Phase 3 | Terminated | German CLL Study Group | 83 | 1999-07-01 | 2016-09-26 |
| Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma tositumomab and iodine I 131 tositumomab - Lymphoma | Phase 3 | Terminated | University of Nebraska | 31 | 1998-11-01 | 2018-01-17 |
| Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation cyclosporine, cyclosporine and methotrexate - Leukemia, Lymphoma | Phase 3 | Terminated | Baxalta now part of Shire | 105 | 1997-04-01 | 2021-05-06 |
Leukemia, Lymphocytic, Chronic, B-Cell (17) · Lymphoma, Follicular (8) · Lymphoma, B-Cell, Marginal Zone (7) · Lymphoma, Mantle-Cell (5) · Lymphoma, Non-Hodgkin (5) · Leukemia (4) · Lymphoma (4) · Lymphoma, Large B-Cell, Diffuse (4) · Burkitt Lymphoma (3) · Leukemia, Myeloid, Accelerated Phase (3) · Leukemia, Myeloid, Chronic-Phase (3) · Lymphoma, Large-Cell, Immunoblastic (3) · Multiple Myeloma (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)
Hematologic Diseases (20) · Hemic and Lymphatic Diseases (20) · Immune System Diseases (20) · Immunoproliferative Disorders (20) · Leukemia, Lymphoid (20) · Lymphatic Diseases (20) · Lymphoproliferative Disorders (20) · Neoplasms by Histologic Type (20) · Neoplasms (18) · Chronic Disease (17) · Disease Attributes (17) · Pathologic Processes (17) · Pathological Conditions, Signs and Symptoms (17) · Leukemia (16)
idelalisib (6) · Rituximab (4) · Bendamustine Hydrochloride (3) · Chlorambucil (3) · ofatumumab (3) · ublituximab (3) · umbralisib (3) · fludarabine (2) · obinutuzumab (2) · Cholecalciferol (1) · Cyclophosphamide (1) · Cyclosporine (1) · Filgrastim (1) · Methotrexate (1) · Mitoxantrone (1)
Gilead Sciences (6) · TG Therapeutics, Inc. (3) · Novartis Pharmaceuticals (2) · Alliance for Clinical Trials in Oncology (1) · Baxalta now part of Shire (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · German CLL Study Group (1) · Martin, Paul (1) · OHSU Knight Cancer Institute (1) · Semmelweis University (1) · University of Alabama at Birmingham (1) · University of Nebraska (1)
United States (17) · France (9) · Poland (9) · Spain (9) · United Kingdom (9) · Australia (8) · Canada (8) · Italy (8) · Belgium (6) · Czechia (5) · Israel (5) · Russia (5) · Sweden (5) · Germany (4) · Hungary (4)
Istvan Takacs, MD, PhD (1) · John C. Byrd, MD (1) · Joseph Bubalo, PharmD, BCPS, BCOP (1) · Julie M. Vose, MD (1) · Marten Beijert, MD (1) · Michael Hallek, MD (1) · Owen A O'Connor, MD, PhD (1) · Paul J. Martin, MD (1) · Pierre Richaud, MD (1) · William P. Vaughan, MD (1)
PMID 19270260, PMID 25103870, PMID 25882396, PMID 28257752, PMID 30916608, PMID 30995176, PMID 32599655, PMID 33054084, PMID 33683917
2015 (1), P30CA036727 (1), P30CA069533 (1), U10CA031946 (1)